
Menstrual cycle irregularities are common during the first few months of use of hormonal contraception and the IUD. Although most contraception-related menstrual problems are not clinically significant, they can lead to erratic method use or even discontinuation. This article presents guidelines for the assessment and management of bleeding problems related to use of combined oral contraceptives (OCs), progestin-only pills, subdermal progestin implants, injections, and IUDs. Much of the patient dissatisfaction that results from these menstrual changes can be averted by careful counseling prior to method selection. Candid dialogue regarding the potential for bleeding disturbances is critical before a method is prescribed in order to avert the interrupted contraceptive practices that place women at risk of unintended pregnancy.
Contraceptive practice guidelines have the potential to assist health care providers in evaluating the needs and expectations of women seeking contraception, educating patients, and monitoring successful contraceptive use. This article presents guidelines for IUD patient selection developed by several members of the editorial board of the US newsletter, "Dialogues in Contraception." Misinformation about the IUD has prevented many clinicians and patients from considering this method, despite recent improvements in its design. The currently available data suggest that the two IUDs available in the US, Copper T 380A and Progestasert, cause a local reaction that is toxic to sperm (and perhaps ova), thereby preventing fertilization. Modern IUDs, which use only monofilament tails, do not increase the risk of pelvic inflammatory disease in women without evidence of lower genital tract infection. Beyond avoiding women at risk for sexually transmitted diseases, there are few barriers to IUD use. The method is appropriate for women who are contemplating but ambivalent about sterilization, aged under 25 years, perimenopausal, nulliparous or parous, postpartum or postabortion, lactating, and cigarette smokers over 35 years of age. Contraindications to IUD use are postpregnancy infection, unresolved acute cervicitis or vaginitis, distorted uterine cavity, uterine or cervical cancer, unexplained abnormal vaginal bleeding, increased susceptibility to infection, genital actinomycosis, immunocompromised patients, and diabetes mellitus (progesterone-releasing IUD only).
Dramatic reductions in both the estrogen and progestin doses of combined oral contraceptives (OCs) have created a need for regular reassessment of safety and side effect issues. The development of OCs with estrogen doses of less than 50 mcg has resulted in fewer adverse hematologic and cardiovascular effects while retaining the contraceptive and noncontraceptive benefits of these agents. This article, intended to help US clinicians make sound OC prescribing recommendations, reviews the effect of the estrogen component of available OCs on adverse cardiovascular effects (venous thrombosis and embolism, myocardial infarction, and thrombotic and hemorrhagic stroke), breast cancer risk, and menstrual cycle control. Although a review of the available research evidence suggests that OC use is associated with a three-fold increase in the risk of venous thromboembolism, this is half of the risk associated with pregnancy. OCs with more than 35 mcg of estrogen should be reserved for women with specific conditions (e.g., concomitant use of hepatic enzyme-inducing drugs). From the perspective of safety, compliance, and noncontraceptive health benefits, OCs containing 30-35 mcg of estrogen represent a more prudent choice for the majority of women than do 20-mcg-dose OCs due, in large part, to the poor cycle control associated with the lowest-dose OCs.
Clinical practice guidelines are important to clarify the potential risks, benefits, and costs of available interventions. Although oral contraceptives (OCs) are the most popular reversible method of fertility control in the US, there are at present no evidence-based guidelines for OC selection. Toward this end, members of the Editorial Board of "Dialogues in Contraception" met to develop initial guidelines for OC selection that reflected both a reasonable interpretation of the available literature and the authors' clinical experiences. Today's OCs contain differing types and doses of estrogen. The central principle in OC prescribing should be that the formulation selected contains the least amount of estrogen and progestin that is possible given the patient's needs. These guidelines divide available OCs into categories of low, medium, and high androgenic activity of the progestin component. The low androgenic progestin-containing OCs are associated with reduced side effects, improved cycle control, improved lipoprotein profile, and enhanced tolerability. Included with the guidelines are tables that classify OCs by their composition, identify OCs with the potential to minimize or manage unwanted side effects, recommend formulations for women with medical conditions, and outline use of OCs for the treatment of gynecologic symptoms.
In the US, 24% of women aged 15-50 rely on female or male sterilization for contraception. While all methods of sexual sterilization are highly effective, new data indicate that the risk of pregnancy after female sterilization varies according to type of procedure performed and the woman's age, but at 18.5/1000 procedures the risk is higher than previously believed. About 30% of all tubal sterilization failures result in ectopic pregnancy, with the greatest risk occurring 2-3 years after the procedure. Female sterilization can be performed at a time unrelated to conclusion of pregnancy or during the postpartum or postabortion periods using the minilaparotomy or laparoscopy surgical approach and surgical ligation or mechanical or electrical occlusion. Location of the vasa deferentia for occlusion in vasectomy can be achieved through two small incisions or with the no-scalpel method. Various methods are used to achieve occlusion. With a first-year pregnancy rate of only 0.15%, vasectomy is superior to female sterilization in terms of efficacy, safety, procedural complexity, and cost. The disadvantages of female sterilization include regret, the rare occurrence of surgical complications, a small risk of death (4/100,000), an increased risk of subsequent hysterectomy among younger women undergoing tubal ligation, and menstrual pain. Tubal sterilization, however, may protect against ovarian cancer. The few disadvantages associated with vasectomy include the small risk of immediate complications and regret. Because of the permanent nature of sterilization, effective counseling is important and should include presentation of information about the reversible, longterm contraceptive methods available to women.